Layered double hydroxides (LDHs) show great potential as CO 2 adsorbent materials, but require improvements in stability and CO 2 adsorption capacity for commercial applications. In the current study, graphene oxide provides a light-weight, chargecomplementary, two-dimensional (2D) material that interacts effectively with the 2D LDHs, in turn enhancing the CO 2 uptake capacity and multicycle stability of the assembly. As a result, the absolute capacity of the LDH was increased by 62% using only 7 wt % graphene oxide (GO) as a support. The experimental procedure for the synthesis of the materials is based on a direct precipitation of the LDH nanoparticles onto GO followed by a structural and physical characterization by electron microscopy, X-ray diffraction, thermogravimetric analysis, and Brunauer−Emmett− Teller (BET) surface area measurements. Detailed titration confirmed the compatibility of the surface chemistry. After thermal decomposition, mixed metal oxides (MMOs) are obtained with the basic sites required for the CO 2 adsorption. A range of samples with different proportions of GO/MMO were prepared, fully characterized, and correlated with the CO 2 sorption capacity, established via TGA.

We used a double-blind, placebo-controlled trial to study the efficacy of WC3 rotavirus vaccine administered to 104 infants (ages, three to 12 months) before the rotavirus season. Forty-nine infants received vaccine; 55 received placebo. Rotavirus disease during this season was predominantly caused by a serotype 1 strain. In placebo recipients there were 14 cases of rotavirus diarrhea (attack rate, 25%); 11 were moderate to severe (attack rate, 20%). Vaccinees experienced only three cases of rotavirus disease (attack rate, 6.1%), all mild. When all cases (whether associated with rotavirus or not) of clinically significant diarrhea (CSD) were evaluated, WC3 vaccine provided statistically significant (P less than .01) protection against the total number of episodes of CSD and reduced the number of days of CSD-associated diarrhea, vomiting, fever, or illness. Seventy-one percent of the WC3-vaccinated infants had serum antibody responses to the vaccine. The 14 placebo recipients who experienced natural disease predominantly had antibody responses to serotype 1. Sera taken after the rotavirus season revealed a nearly identical rate (40%) of natural rotavirus infection in the vaccinated and placebo groups.

Rotavirus strains belonging to G types 1 to 4 and having a P3 genotype (M37-1ike VP4) were recovered from children with symptomatic and asymptomatic infections. Partial sequences of their VP4 genes were determined in an attempt to characterize these strains further. The genomic regions encoding VP8*, the connecting and putative fusion peptides and three other regions in VP5* were sequenced. The deduced amino acid sequences were compared with rotavirus strains belonging to different P genotypes that had been previously reported. High degrees of identity were found between the VP8* fragment of all human P3 strains (92"7 to 99-7%) suggesting that they belong to the same genotype, regardless of differences in their virulence. Furthermore, based on comparative sequence analysis, we did not identify any amino acid(s) that differ appreciably between symptomatic and asymptomatic strains and could therefore be associated with virulence. The results suggest that the P3 genotype, although frequently associated with asymptomatic infections, may not be the single determining factor in attenuation of symptoms.

No abstract

No abstract